New MRI scan could spot bone lesions without radiation

NCT ID NCT06988020

First seen Apr 25, 2026 · Last updated Jun 22, 2026 · Updated 11 times

Summary

This study tests an improved whole-body MRI that uses special 'pseudo-CT' sequences to detect bone lesions in people with multiple myeloma. The goal is to see if this single, radiation-free scan can accurately find bone damage. About 45 patients with newly diagnosed or recurrent myeloma will be scanned, and the results will be compared to standard imaging methods.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA BONE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Cliniques universitaires Saint-Luc

    RECRUITING

    Brussels, Belgium

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

MRI with ZTE sequences

What this could lead to

If successful, this MRI technique could become a more accurate, radiation-free way to detect bone lesions in multiple myeloma patients.

What could go wrong

This is a small, early-phase diagnostic study (45 participants) focused on accuracy, not treatment. The new sequences may not prove significantly better than current methods.

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.